Entropy Neurodynamics posts breakthrough 75% response in treatment-resistant IBS trial

Tryptamine Therapeutics ( (AU:ENP) ) has shared an announcement.

Entropy Neurodynamics reported breakthrough Phase 2a data showing its oral psilocybin candidate TRP-8802 achieved a 75% response rate in 12 patients with treatment-resistant irritable bowel syndrome, far exceeding the 17–44% response seen with current approved therapies. The open-label trial, presented at the Digestive Disease Week 2026 congress by researchers from Massachusetts General Hospital and Columbia University, also demonstrated encouraging responses across IBS subtypes and a safety profile consistent with psychedelic-assisted therapy.

Clinical benefit was closely linked to improvements in psychological flexibility and insight, supporting the gut-brain axis mechanism and suggesting TRP-8802 targets root-cause neurobiological pathways rather than merely masking symptoms. Management says the results significantly de-risk development of its IV psilocin candidate TRP-8803, strengthen the company’s position for partnerships and grant funding, and enhance its prospects in the sizeable IBS market, where U.S. patients spend over US$60 billion annually on treatments.

More about Tryptamine Therapeutics

Entropy Neurodynamics Limited is an ASX-listed clinical-stage biotechnology company focused on developing psychedelic-assisted therapies, including psilocybin and psilocin-based candidates, for hard-to-treat chronic conditions. The company is targeting large unmet needs such as treatment-resistant irritable bowel syndrome in major markets, with an emphasis on establishing a clear U.S.-focused development pathway.

Average Trading Volume: 2,334,327

Technical Sentiment Signal: Buy

Current Market Cap: A$60.38M

Learn more about ENP stock on TipRanks’ Stock Analysis page.